Drugs & 
Pill 
Drug Interaction 
Symptom 
Side 
Conditions 
Treatment 
Compare 
My Med 
Discount 
FDA 
Price 
Phonetic 
Health Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Keytruda (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy
(BUSINESS WIRE) June 13, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Zusduri (mitomycin) for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
(BUSINESS WIRE)--Jun. 12, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative...
U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for Mavyret (glecaprevir/pibrentasvir),...
FDA Approves Ibtrozi (taletrectinib) for Advanced ROS1-Positive Non-Small Cell Lung Cancer
(BUSINESS WIRE) June 11, 2025 -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer...
FDA Approves Xifyrm (meloxicam) Injection for the Management of Moderate-to-Severe Pain in Adults
Woburn, MA — June 10, 2025 — Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Xifyrm...
FDA Approves Enflonsia (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants
(BUSINESS WIRE) June 9, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration...
FDA Approves Widaplik (telmisartan, amlodipine and indapamide) for the Treatment of Hypertension
London, UK, Boston, MA, 9 June 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing unmet needs in cardiometabolic...
New COVID Variant, NB.1.8.1, May Now Make Up 1 in 3 U.S. Cases
MONDAY, June 16, 2025 — A new COVID-19 variant that led to a spike in hospital cases across parts of Asia may now account for more than one-third of...
Bugaboo Recalls 18,000+ Giraffe High Chairs Due to Fall Risk
MONDAY, June 16, 2025 — Parents, take note: Bugaboo is recalling more than 18,000 of its Giraffe high chairs following reports of the legs separating...
Rheumatoid Arthritis On The Rise Worldwide, AI-Powered Study Estimates
MONDAY, June 16, 2025 — Rheumatoid arthritis (RA) has steadily increased around the world during the past three decades, a new AI-powered study reports.The...
COVID Vaccine Protects Against Kidney Damage During Infection
MONDAY, June 16, 2025 — Kidney damage is common during a severe case of COVID-19, but vaccination appears to protect people against this life-threatening...
Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma
MILAN (June 13, 2025) – Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study...
Doctors' Preferences for Their Own End-of-Life Care? No Life-Sustaining Practices
Many physicians would personally prefer to avoid life-sustaining practices if they had advanced cancer or Alzheimer disease, according to a study published...
Few Adolescents With Obesity Prescribed Obesity Medications
Despite an increase in the prevalence of prescribing, only 0.5 percent of U.S. adolescents with obesity were prescribed an obesity medication in 2023,...
Decline in Youth Physical Fitness Seen in Association With Pandemic
During the early days of the COVID-19 pandemic, there was a decline in the physical fitness of U.S. youth, according to a study published online June 4...
Mindfulness, Transcranial Stimulation Promising for Urgency Urinary Incontinence
Mindfulness (MI) and transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex offer therapeutic benefit for reducing situational...
Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer
Lund, Sweden – 13 June 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed...
Blood Tests Can Detect Cancer Years Earlier
TUESDAY, June 10, 2025 — Blood tests can detect evidence of cancer three years earlier than the disease would otherwise be diagnosed, a new small-scale...
Recently Added
Recently added consumer and prescribing information: Ibtrozi, Miudella, Opdivo Qvantig, Alyftrek, Crenessity, Ensacove, Steqeyma, Yesintek, Revuforj, Danziten
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex CareNotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Zusduri Zusduri (mitomycin) is a sustained release, hydrogel-based formulation of mitomycin for intravesical treatment of low-grade...
- Ibtrozi Ibtrozi (taletrectinib) is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic...
- Xifyrm Xifyrm (meloxicam) is a non-steroidal anti-inflammatory drug (NSAID) for use in the management of moderate-to-severe pain.
Drug Information
Tools
- Interaction Checker
- Pill Identifier
- Symptom Checker
- Medication Record
- Mobile Apps
- Drug Imprint Codes
- Community Support
- Compare Drugs
News & Alerts
- Medical News
- Clinical Trial Results
- FDA Drug Alerts
- FDA Consumer Updates
- New FDA Approvals
- New Drug Applications
- Drug Shortages
- Video Center
- Popular Articles
Professionals
Top 100 Drugs
- Abilify
- Adderall
- Aimovig
- Ambien
- Atorvastatin
- Austedo
- Avastin
- Benlysta
- Biktarvy
- Botox
- Breztri
- Buprenorphine
- Cabenuva
- Cimzia
- Cosentyx
- Diazepam
- Descovy
- Diclofenac
- Doxycycline
- Duloxetine
- Dupixent
- Emgality
- Enhertu
- Entyvio
- Epclusa
- Erleada
- Evenity
- Fasenra
- Farxiga
- Gabapentin
- Gemtesa
- Humira
- Ibuprofen
- Imbruvica
- Januvia
- Jardiance
- Kesimpta
- Keytruda
- Kisqali
- Leqembi
- Leqvio
- Lexapro
- Lybalvi
- Lyrica
- Metformin
- Methadone
- Methotrexate
- Mounjaro
- Naloxone
- Naltrexone
- Nucala
- Nurtec
- Ofev
- Opdivo
- Orladeyo
- Otezla
- Oxycodone
- Ozempic
- Paxlovid
- Penicillin
- Praluent
- Prednisone
- Prozac
- Qulipta
- Quviviq
- Reblozyl
- Repatha
- Restasis
- Rexulti
- Rybelsus
- Semaglutide
- Seroquel
- Sildenafil
- Skyrizi
- Sotyktu
- Stelara
- Sublocade
- Taltz
- Tepezza
- Tramadol
- Tremfya
- Trintellix
- Tylenol
- Ubrelvy
- Vabysmo
- Venclexta
- Verzenio
- Viagra
- Vijoice
- Vraylar
- Vumerity
- Vyepti
- Vyvanse
- Vyvgart
- Wegovy
- Wellbutrin
- Xanax
- Xolair
- Xyrem
- Zepbound
